The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to account for new, bivalent formulations designed to install immunity against the SARS-CoV-2 omicron variant. FDA will refer to the bivalent doses in literature as “updated doses,” which contain two messenger RNA components of SARS-CoV-2 virus: one of the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2. 
 
According to the FDA, individuals 18 years of age and older are eligible for a single booster dose of the Moderna COVID-19 Vaccine, Bivalent if they are at least two months removed from the completion of their primary vaccination series or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent booster is authorized as a single booster dose for individuals 12 years of age and older who are at least two months removed from the completion of their completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. 
 
The EUA expressly instructs providers to no longer use the monovalent booster shots; instead, patients are to be rescheduled for on-the-books booster appointments and return after the bivalent boosters’ official approval. 
 
In related news, the American Medical Association announced an editorial update to Current Procedural Terminology with eight new codes for the Pfizer and Moderna bivalent COVID-19 vaccine booster doses. 

Related News Articles

Perspective
As we move into fall and winter, we know the viruses that cause respiratory disease will usually circulate more heavily in communities. Already, the Centers…
Headline
In these video snippets from an AHA Advancing Health podcast series, health care leaders and clinicians from four children's hospitals share how they worked to…
Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…